An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens

Trial Profile

An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Daptomycin (Primary) ; Clindamycin; Penicillins; Vancomycin
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 15 Feb 2017 Results published in the Pediatrics.
    • 19 Mar 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2013 as reported by ClinicalTrials.gov record.
    • 19 Mar 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Oct 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top